NCT06787911

Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer

The Efficacy and Safety of Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: Yu Wang · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm intervention study. Locally advanced differentiated thyroid carcinoma patients receive neoadjuvant therapy with Donafenib and PD-1 antibody Sintilimab and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to evaluate the efficacy and safety of Donafenib combined with PD-1 antibody in neoadjuvant therapy of locally advanced thyroid cancer.

Conditions

• Thyroid Cancer

Interventions

Type	Name	Description
DRUG	Donafeib with Sintilimab	Patients receive Donafenib and PD-1 antibody Sintilimab

Timeline

• Start date: 2024-07-24
• Primary completion: 2025-05-31
• Completion: 2026-09-30
• First posted: 2025-01-22
• Last updated: 2025-01-22

Locations

1 site across 1 country: China